SCHEMBL10205865

SCHEMBL10205865

CC1(C)C(=O)Nc2cccc(CNc3nc(Nc4ccc(C5CCN(C(=O)C6CCCN6)CC5)cc4)ncc3Br)c21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 3/20 0.43
▸ STAT6 P42226 1/20 0.41
▸ SYK P43405 1/20 0.39
▸ CDK1 P06493 1/20 0.38
▸ CCR4 P51679 1/20 0.37
▸ BTK Q06187 1/20 0.37
▸ TBK1 Q9UHD2 4/20 0.37
▸ IGF1R P08069 1/20 0.37
▸ NTRK1 P04629 2/20 0.37
▸ NUAK1 O60285 1/20 0.37
▸ STK16 O75716 1/20 0.37
▸ CSNK2A2 P19784 1/20 0.37
▸ TYK2 P29597 1/20 0.37
▸ BMPR2 Q13873 1/20 0.37
▸ AAK1 Q2M2I8 1/20 0.37
▸ NUAK2 Q9H093 1/20 0.37
▸ MKNK2 Q9HBH9 1/20 0.37
▸ BMP2K Q9NSY1 1/20 0.37
▸ PTK2 Q05397 2/20 0.37
▸ FLT4 P35916 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10205861 0.97 STAT6 (0.43) TNK2STAT6SYKCDK1BTK
SCHEMBL10206602 0.93 TNK2 (0.43) TNK2STAT6CCR4NTRK1FLT4
SCHEMBL10205862 0.91 STAT6 (0.42) TNK2STAT6SYKCDK1BTK
SCHEMBL10205863 0.87 STAT6 (0.43) TNK2STAT6SYKCDK1BTK
SCHEMBL14331602 0.87 STAT6 (0.43) TNK2STAT6SYKCDK1BTK
SCHEMBL10207050 0.85 TNK2 (0.54) TNK2CDK1BTKPTK2FLT4
SCHEMBL10206634 0.85 STAT6 (0.44) TNK2STAT6SYKCDK1TBK1
SCHEMBL10207024 0.84 TNK2 (0.46) TNK2CDK1IGF1RNTRK1PTK2
SCHEMBL10205216 0.83 STAT6 (0.42) TNK2STAT6CDK1IGF1RPTK2
SCHEMBL10206198 0.83 STAT6 (0.42) TNK2STAT6CDK1TBK1IGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655358-B1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2014-11-19 — — EP disclosed
US-8546443-B2 Benzylic oxindole pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 — — US disclosed
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-27 — — US disclosed
WO-2012085126-A1 OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120329771-A1 BENZYLIC OXINDOLE PYRIMIDINES MKI67, CCNI, CCNB1 TNK2 646/4885STAT6 1155/4885SYK 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback